Skip to main content
. 2024 May 25;25(11):5760. doi: 10.3390/ijms25115760

Table 3.

Surgical treatment and outcomes.

Author n Surgical Management Outcomes
Goyal [12] 644 Different interventions:

  1. Punch/shave/incisional: 19.8%

  2. Excisional biopsy: 0.5%

  3. Biopsy followed by electrodessication/cryosurgery/laser: 0.5%

  4. Excision < 1 cm margin: 76.6%

  5. Excision > 1 cm margin: 2.7%

 5-year disease specific survival:
  • 1.

    96.3%

  • 2.

    98.8%

  • 4.

    99.3%

  • 5.

    99.1%
Rao [17] 8 Periungual PC
  • -

    Amputation: 62.5%

  • -

    Excision 37.5%

 Recurrence: 25% (not further specified)
Prieto-Granada [16] 28 WLE (1–2 cm margin) in all patients
SLNB: 19% (0% positive)
LND: 21% (in case of positive nodes)		 Local recurrence: 11%
Regional recurrence: 14%
Nazemi [11] 206 Primary PC: (n = 160)
  • -

    WLE: 55% (1 cm margin)

  • -

    MMS 26.2%

  • -

    Amputation 2.5%

LN disease: (n = 35)
  • -

    WLE: 11.4%

  • -

    WLE + LND: 22.8%

  • -

    Amputation + LND 14.3%

  • -

    WLE + LND + ART: 11.4%

  • -

    WLE + ART: 8.6%

  • -

    WLE + ACT: 11.4%

  • -

    WLE + ACT + ART: 5.7%

  • -

    Amputation 2.9%

  • -

    ECT + LND 2.9%

 Primary tumors:
  • -
    WLE compared to MMS:
    • ○
      AWOD: 56.8% vs. 83%
    • ○
      LN metastasis: 11.4% vs. 2.4%
Nodal metastasis:
  • -
    WLE:
    • ○
      AWOD (180 months) in 25%, additional LN metastasis in 25% (4 months)
  • -
    WLE + LND
    • ○
      DM in 50% (6.5 months), additional LN metastasis in 25% (9.8 months)
  • -
    Amputation + LND:
    • ○
      AWOD in 40%, DM in 20% (7 months both)
  • -
    WLE + LND + ART
    • ○
      AWOD (12 months) in 25%, DM in 50% (4.5 months)
  • -

    WLE + ART/WLE + CHT/ECT + LND

  • -

    : AWOD 100% (5–48 months)
Yazar [8] 7 Excision:
  • -

    Single stage: 42% (mean margin of 1.28 mm)

  • -

    Double stage: 57% (mean margin 8.83 mm)

SLNB: 28% of patients (when tumor dept ≥3 mm)
LND: 14% (tumor diameter >4.5 cm)		 No positive nodes at diagnosis
Follow up (mean 36 months)
  • -

    No recurrences

  • -

    No metastasis
Kim [14] 37 WLE: 64.9%
WLE + ART: 5.4%
WLE + LND + ACT: 2.7%
MMS: 5.4%		 No outcomes after surgery reported
Le NS [15] 116 WLE: 76.7%
MMS: 15.8% (2 stages in 63.2%)
LND: 15% (of which 72.2% at diagnosis and 27.8% at recurrence)
Radiotherapy: 16.7%
  • -

    Primary 5%

  • -

    Adjuvant: 55%

  • -

    Recurrence: 15%

  • -

    Metastasis): 20%

CHT: 10.8%
  • -

    Primary: 15.2%

  • -

    Adjuvant: 30.8%

  • -

    Recurrence: 23.1%

  • -

    Metastasis: 23.1%

 Local recurrence: (p = 0.084)
  • -

    WLE: 14.7%

  • -

    MMS: 0%

Regional recurrence: (p = 0.017)
  • -

    WLE: 25.3%

  • -

    MMS: 0%

DM (p = 0.181)
  • -

    WLE: 8.8%

  • -

    MMS: 0%

Significantly higher mortality rate after local and regional recurrence and metastasis.
Only significant difference in 3-year OS for DM.
Tolkachjov [23] 46 MMS After MMS:
Nodal metastasis: 4.2%
Local recurrence, DM and disease specific mortality 0%
De Georgi [13] 133 Surgery: 99% (margins not specified)
CHT: in selected cases (indications not specified)		 Local recurrence: 2.3% after 48.7 months.

WLE: wide local excision, SLNB: sentinel lymph node biopsy, LND: lymph node dissection, MMS: Mohs micrographic surgery, ART: adjuvant radiotherapy, ACT: adjuvant chemotherapy, ECT: electrochemotherapy, CHT: chemotherapy.